Gil Rabinovici, MD, is a professor in the UCSF Department of Neurology and holds the Edward and Pearl Fein Distinguished Professorship in Memory and Aging. He is a behavioral neurologist at the UCSF Edward and Pearl Fein Memory and Aging Center (Fein MAC), where he cares for individuals with cognitive disorders. Dr. Rabinovici earned his bachelor’s degree from Stanford University and his medical degree from Northwestern University Feinberg School of Medicine. He completed his neurology residency, including a year as chief resident, at UCSF, followed by a fellowship in behavioral neurology at the Fein MAC.
Dr. Rabinovici’s research focuses on using structural, functional, and molecular brain imaging to improve the diagnosis of dementia and advance the understanding of neurodegenerative diseases. His work aims to accelerate drug development and improve care for people living with Alzheimer’s disease and related disorders. He directs the NIH-funded UCSF Alzheimer’s Disease Research Center and leads several large-scale studies, including the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies, which together have enrolled approximately 25,000 participants. He also serves as co-principal investigator (co-PI) of the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), the Longitudinal Evaluation of Alzheimer’s Disease Study (LEADS), the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI), and DIAGNOSE CTE Project-II. His research is supported by the NIH, the Alzheimer’s Association, the Rainwater Charitable Foundation, the American College of Radiology, and industry collaborators.
Dr. Rabinovici has authored more than 350 peer-reviewed publications, with his work ranked in the top 1% in the field of Neuroscience. His contributions have been recognized with numerous honors, including the 2025 Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases from the American Academy of Neurology and the American Brain Foundation, the 2022 Kuhl-Lassen Award from the Society of Nuclear Medicine and Molecular Imaging, and the 2015 Christopher Clark Award in Amyloid Imaging.